06:38 AM EDT, 07/21/2025 (MT Newswires) -- Alkermes ( ALKS ) said Monday that a phase 2 study of alixorexton in patients with narcolepsy type 1 met the primary endpoint across all doses tested.

Results showed "statistically significant, clinically meaningful and dose-dependent improvements" from baseline, compared with placebo on the maintenance of wakefulness test, the company said.

Alixorexton also showed "robust and clinically meaningful improvements" compared with placebo on patient-reported outcomes tied to excessive daytime sleepiness and other key symptoms, Alkermes ( ALKS ) said, adding that the treatment was generally well tolerated at all doses tested.

The data support "rapid initiation" of a global phase 3 program of alixorexton in narcolepsy type 1, the company said.

Narcolepsy type 1 is a neurological sleep disorder.

Alkermes ( ALKS ) shares were up 5.1% in recent premarket activity.